Serum Gastrin in Zollinger-Ellison Syndrome I. Prospective Study of Fasting Serum Gastrin in 309 Patients From the National Institutes of Health and Comparison With 2229 Cases From the Literature

2007 ◽  
Vol 2007 ◽  
pp. 172-173
Author(s):  
T.J. Fahey
Keyword(s):  
Prospective Study ◽  
Serum Gastrin ◽  
National Institutes Of Health ◽  
Fasting Serum ◽  
Zollinger Ellison Syndrome

Gastrin Response to Calcium Infusion: An Aid to the Improved Diagnosis of Zollinger-Ellison Syndrome in Children

PEDIATRICS ◽  
1974 ◽  
Vol 54 (5) ◽  
pp. 599-602
Author(s):  
David L. Schwartz ◽  
John J. White ◽  
Frank Saulsbury ◽  
J. Alex Haller
Keyword(s):  
Serum Gastrin ◽  
Islet Cell Tumor ◽  
Elevated Serum ◽  
Cell Tumor ◽  
Infusion Test ◽  
Fasting Serum ◽  
Zollinger Ellison Syndrome ◽  
Weight One ◽  
Calcium Infusion ◽  
One Year

Serum gastrin levels were equivocally elevated in a 9-year-old boy with suspected Zollinger-Ellison syndrome. He had copious hyperacidity on fasting gastric analysis which was increased insignificantly following histamine administration. A calcium infusion test produced diagnostically elevated serum gastrin values (average 400 pg/ml) which were sustained for the course of the four-hour infusion. A malignant islet cell tumor of the pancreas metastatic to a celiac lymph node was found, and total gastrectomy performed. The boy adjusted well and is gaining along his curves for height and weight one year postoperatively. The calcium infusion test, or its counterpart the calcium challenge, appears to be a helpful method for identifying the Zollinger-Ellison syndrome, particularly in children in whom fasting serum gastrin values may not be diagnostic by adult standards.

Prognostic Value of Initial Fasting Serum Gastrin Levels in Patients With Zollinger-Ellison Syndrome

2001 ◽  
Vol 19 (12) ◽  
pp. 3051-3057 ◽  
Author(s):  
Adam C. Berger ◽  
Fathia Gibril ◽  
David J. Venzon ◽  
John L. Doppman ◽  
Jeffrey A. Norton ◽  
...  
Keyword(s):  
Lymph Node ◽  
Liver Metastases ◽  
Tumor Size ◽  
Primary Tumor ◽  
Serum Gastrin ◽  
Hepatic Metastases ◽  
Initial Evaluation ◽  
Fasting Serum ◽  
Men 1 ◽  
Zollinger Ellison Syndrome

PURPOSE: To assess the value of the initial fasting serum gastrin (FSG) at presentation in patients with Zollinger-Ellison Syndrome (ZES) in predicting primary tumor characteristics and survival. PATIENTS AND METHODS: A total of 239 patients were treated for ZES between December 1981 and September 1998, with a mean follow-up of 9.1 ± 0.6 years. At initial evaluation, 86 patients (36%) had mild (0 to 499 pg/mL), 61 (25.5%) had moderate (500 to 1,000 pg/mL), and 92 (38.5%) had severe (> 1,000 pg/mL) elevations in FSG. Primary tumor location and size, presence of lymph node or hepatic metastases, and survival were analyzed based on the level of initial FSG. RESULTS: In patients with sporadic ZES, but not in those with multiple endocrine neoplasia type 1 (MEN-1) and ZES, there was a significant relationship between the level of initial FSG and tumor size and location of primary tumor, frequency of lymph node and liver metastases, and survival. The median 5- and 10-year survival decreased with increasing initial FSG (P < .001) in patients with sporadic ZES; MEN-1 patients lived longer than sporadic ZES patients (P = .012), and survival in this group was not associated with the level of initial FSG. Multivariate analysis showed that factors independently associated with death from disease in patients with sporadic ZES were liver metastases (P = .0001), a pancreatic site (P = .0027), and primary tumor size (P = .011) but not initial FSG (P > .30). CONCLUSION: The severity of FSG at presentation is associated with size and site of tumor and the presence of hepatic metastases, factors that are significant independent predictors of outcome. The level of FSG at presentation may be useful in planning the nature and extent of the initial evaluation and management in patients with sporadic ZES.

scholarly journals S3070 Zollinger-Ellison Syndrome: A Fasting Serum Gastrin Level Is Not Enough

2021 ◽  
Vol 116 (1) ◽  
pp. S1267-S1267
Author(s):  
Ann Saliares ◽  
Veena Janardan ◽  
Fadi Hawa ◽  
Naresh Gunaratnam
Keyword(s):  
Serum Gastrin ◽  
Gastrin Level ◽  
Serum Gastrin Level ◽  
Fasting Serum ◽  
Zollinger Ellison Syndrome

scholarly journals Serum Gastrin Levels in Malignant Zollinger-Ellison Syndrome after Total Gastrectomy and Hypophysectomy

1970 ◽  
Vol 172 (3) ◽  
pp. 504-521 ◽  
Author(s):  
STANLEY R. FRIESEN ◽  
ROBERT E. BOLINGER ◽  
A. G. E. PEARSE ◽  
JAMES E. MCGUIGAN
Keyword(s):  
Total Gastrectomy ◽  
Serum Gastrin ◽  
Zollinger Ellison Syndrome

scholarly journals Prospective Study of the Natural History of Gastrinoma in Patients with MEN1: Definition of an Aggressive and a Nonaggressive Form

2001 ◽  
Vol 86 (11) ◽  
pp. 5282-5293 ◽  
Author(s):  
Fathia Gibril ◽  
David J. Venzon ◽  
Jeremiah V. Ojeaburu ◽  
Showkat Bashir ◽  
Robert T. Jensen
Keyword(s):  
Natural History ◽  
Tumor Growth ◽  
Prospective Study ◽  
Liver Metastases ◽  
Hepatic Metastases ◽  
Endocrine Tumors ◽  
Zollinger Ellison Syndrome ◽  
Pancreatic Endocrine Tumors ◽  
History Of ◽  
Aggressive Tumor

The natural history of pancreatic endocrine tumors (PETs) in patients with MEN1 is largely unknown. Recent studies in patients with sporadic PETs show that in a subset, tumor growth is aggressive. To determine whether PETs in patients with MEN1 show similar growth behavior, we report results from a long-term prospective study of 57 patients with MEN1 and Zollinger-Ellison syndrome. All patients had tumor imaging studies yearly, and the mean follow-up was 8 yr. Only patients with PETs 2.5 cm or larger underwent abdominal surgical exploration. Hepatic metastases occurred in 23%, and in 14% tumors demonstrated aggressive growth. Three tumor-related deaths occurred, each due to liver metastases, and in each, aggressive tumor growth was present. Overall, 4% of the study group, 23% with liver metastases and 38% with aggressive disease, died. Aggressive growth was associated with higher gastrins and larger tumors. Patients with liver metastases with aggressive growth differed from those with liver metastases without aggressive growth in age at MEN1 onset or diagnosis and primary tumor size. Survival was decreased (P = 0.0012) in patients with aggressive tumor growth compared with those with liver metastases without aggressive growth or with no liver metastases without aggressive growth. Based on these results a number of factors were identified that may be clinically useful in determining in which patients aggressive tumor growth may occur. These results demonstrate in a significant subset of patients with MEN1 and Zollinger-Ellison syndrome, aggressive tumor growth occurs and can lead to decreased survival. The identification of prognostic factors that identify this group will be important clinically in allowing more aggressive treatment options to be instituted earlier.

Sign in / Sign up

Export Citation Format

Share Document